Introduction
Ovarian cancer is the most deadly gynecologic malignancy. About 26 500 women are diagnosed with this cancer each year and have an overall 5-year survival rate of only 47% (Ozols, 1999) . For most patients, surgery alone does not cure the cancer due to the spread of tumors beyond the con®nes of the ovary, and management in the clinic often requires use of toxic chemotherapy regimens. The progressive growth and spread of ovarian cancer depends, in part, on the formation of an adequate blood supply, and tumor angiogenesis has been reported to have prognostic signi®cance in epithelial ovarian cancer (Alvarez et al., 1999) . Therapy directed toward the vasculature of solid tumors is now being pursued as an important new direction in cancer treatment because avascular tumors exhibit only limited growth and tumor aggressiveness, and metastatic potential commonly correlates with tumor vascularity (Folkman, 1971; Gimbrone et al., 1972) .
Vascular endothelial growth factor (VEGF) is produced by most solid tumors and elicits a mitogenic eect on tumor-associated endothelial cells (Keck et al., 1989; Leung et al., 1989) . VEGF binding to receptor tyrosine kinases triggers activation of downstream signaling enzymes, including MAP kinase, which, in turn, regulate gene expression and speci®c endothelial cell responses including proliferation, migration, dierentiation and apoptosis (Soker et al., 1996; Rousseau et al., 1997) . Several studies suggest that VEGF plays an important role in progression of ovarian cancer (Paley et al., 1997; Yamamoto et al., 1997; Alvarez et al., 1999) , and the ability of VEGF to increase vascular permeability (Ferrara et al., 1993; Keck et al., 1989; Leung et al., 1989) may also promote formation of malignant ascites (Zebrowski et al., 1999) . Growth factor pathways, such as those dependent on the HER-2 receptor, appear to up-regulate VEGF production in some solid tumors (Petit et al., 1997) . Since HER-2 receptor is overexpressed in a signi®cant number of ovarian cancers (Slamon et al., 1989; Wong et al., 1995; Hellstrom et al., 2001) , it may also play a role in promoting further growth of ovarian malignancy by increasing VEGF-dependent tumor angiogenesis.
Squalamine, a natural sterol from tissues of the dog®sh shark (Moore et al., 1993) , has signi®cant antiangiogenic and antitumor activity in laboratory models of brain, breast and lung cancer (Sills et al., 1998; Teicher et al., 1998; Schiller and Bittner, 1999) . Squalamine is a 7,24-dihydroxylated 24-sulfated cholestane steroid conjugated to spermidine at C-3. Squalamine blocks endothelial cell growth and has inhibitory activity in chick embryo chorioallantoic membrane and rabbit corneal micropocket assays (Sills et al., 1998; Williams, 1999) . This anti-angiogenic agent may have good potential for clinical application because it inhibits endothelial cell proliferation induced by a wide range of growth factors, including VEGF (Sills et al., 1998) . This inhibition may result, in part, from its interaction with endothelial cell surface proton pumps, thereby altering intracellular pH and impeding signaling by growth factors (Akhter et al., 1999; Eckhardt, 1999) . However, a receptor with high anity for binding squalamine has not yet been identi®ed. When administered as a single agent in nude mice with lung cancer xenografts, squalamine has limited antitumor activity, but the antiangiogenic steroid signi®cantly enhances the antitumor ecacy of cisplatin and carboplatin/paclitaxel chemotherapies (Teicher et al., 1998; Schiller and Bittner, 1999; Williams, 1999) . Since platinum-based treatments are often used for human ovarian cancers (Ozols, 1999) , squalamine in combination with cisplatin was studied to assess its utility as part of a coordinated attack against human ovarian cancers and their blood supply. One additional feature we were particularly interested in was the consequence of HER-2 oncogene overexpression for squalamine modulation of growth in ovarian tumor xenografts. Ampli®cation and/or overexpression of HER-2 proto-oncogene in human cancers, including ovarian cancers, is often associated with poor clinical outcome (Slamon et al., 1989; Wong et al., 1995) , and human ovarian tumor cells with overexpression of HER-2 membrane receptor also exhibit resistance to cisplatin (Pegram et al., 1997) . We therefore examined whether the level of HER-2 expression in paired HER-2-transfected and non-transfected ovarian cancers in¯u-enced the degree of tumor growth inhibition seen with squalamine with or without concomitant platinumbased treatment.
Results
Squalamine and platinum-based chemotherapeutics block growth of ovarian tumor xenografts in vivo Potential antitumor eects of the angiostatic steroid squalamine were assessed in murine tumor xenografts in the absence and presence of cisplatin chemotherapy. Human ovarian 2008 cancer cells without ( Figure 1a ) or with HER-2 overexpression ( Figure 1b) were grown as subcutaneous tumors in nude mice. Tumors were grown to 150 ± 200 mm 3 in size. Then, animals with established tumors were treated with control solution, cisplatin alone, squalamine alone (2 mg/kg) on days 1 ± 10, or cisplatin in combination with squalamine (days 1 ± 10). Ovarian 2008 HER-2-overexpressing cancer cells were inoculated subcutaneously in nude mice. After 7 days, animals with tumors of comparable size were randomized to treatment with control vehicle (CON), squalamine (SQ; 2 mg/kg on days 1 ± 10), cisplatin at two dierent doses (Pt 1=4 mg/kg on day 1; Pt 2=5 mg/kg on days 1, 8), or cisplatin administered in combination with squalamine (SQ/Pt 1; or SQ/Pt 2). At the end of the experiment, HER-2 receptor expression levels were assessed and, as possible, con®rmed to be low in parental tumors and high in HER-2-overexpressing xenografts. Results are expressed as mean+s.e.m. for tumor volumes (mm 3 ) measured over a 28-day experimental period Cisplatin was administered at two dierent dose levels (see Pietras et al., 1994; Pegram et al., 1997) . In one set of experiments, animals were treated with a high dose of cisplatin near the maximum tolerated dose (5 mg/kg on day 1 and day 8; Pt 2). In the second set of experiments, lower doses of cisplatin that resulted in only partial growth inhibition (4 mg/kg on day 1; Pt 1) were chosen in order to ensure use of the chemotherapeutic agent at a level that would not totally suppress tumor growth, thus allowing detection of any potential additive eects of a squalamine-cisplatin interaction. By 28 days, both 2008 parental ( Figure 1a ) and HER-2-overexpressing ( Figure  1b ) tumors showed little overall response to therapy with the lower dose of cisplatin alone (both at P40.05). However, 2008 parental (P50.01) and HER-2-overexpressing (P50.05) tumors exhibited some minor responses to cisplatin administered at high doses (see Figure 1 ). Squalamine elicited a partial reduction in tumor size as compared to controls (P50.01) in both 2008 parental ( Figure 1a ) and HER-2-overexpressing ( Figure 1b) tumors. More profound tumor growth inhibition (94 ± 95% of controls) was elicited by combined treatment with squalamine and cisplatin (P50.001) in both 2008 parental ( Figure 1a ) and HER-2-overexpressing (Figure 1b) cancers. This eect of combination therapy was found when squalamine was administered with either low or high doses of cisplatin.
The antitumor eects of squalamine with and without platinum-based chemotherapy were also assessed using a dierent ovarian tumor xenograft, CAOV3, that has been transfected to exhibit HER-2 overexpression (Figure 2a ). After tumor growth to 50 ± 60 mm 3 , animals were treated with control solution, carboplatin alone (60 mg/kg) on day 1, squalamine alone (2 mg/kg) on days 1 ± 10, or carboplatin (day 1) in combination with squalamine (days 1 ± 10). By 28 days, CAOV3 HER-2-overexpressing tumors showed minimal response to therapy with carboplatin at a dose below the maximum tolerated dose ( Figure 2a) . As with the 2008 tumors, squalamine as a single agent elicited a partial reduction in CAOV3 tumor size as compared to controls (P50.05) ( Figure  2a ). More marked inhibition of tumor growth was elicited by combined treatment with squalamine and carboplatin (P50.001; Figure 2a) .
The tumor growth inhibition seen with combined squalamine and platinum-based chemotherapeutics for both human ovarian tumor lines persisted for up to 18 days following cessation of squalamine treatment. We therefore investigated how long bioactivity persisted with combined cisplatin and squalamine treatment of HER-2-overexpressing CAOV3 tumors by maintaining the dual therapy animal cohort until the mean tumor size for these animals reached 500 mm 3 (Figure 2b ). After tumor growth to 50 ± 60 mm 3 , animals with established tumors were treated with control solution, cisplatin alone (4 mg/kg) on day 1, squalamine alone (2 mg/kg) on days 1 ± 10, or cisplatin (day 1) in combination with squalamine (days 1 ± 10). As compared with control tumor xenografts, the calculated tumor growth delay in established tumors was 7 days for cisplatin therapy alone, 28 days for squalamine treatment alone, and 91 days for squalamine combined with cisplatin administration (Figure 2b ). Combined squalamine-cisplatin therapy was nontoxic as assayed by no animal death or signi®cant weight loss during the study period.
Squalamine and cisplatin promote ovarian tumor cell apoptosis in vivo To assess molecular eects of squalamine and cisplatin, ovarian 2008 parent and HER-2-overexpressing tumor Figure 2 Squalamine inhibits growth of ovarian CAOV3 tumor xenografts with HER-2 overexpression and enhances the cytotoxic eects of cisplatin and carboplatin. (a) CAOV3 ovarian cancer cells were inoculated subcutaneously in nude mice. After 7 days, animals with tumors of comparable size were randomized to treatment with control solution (CON), squalamine (SQ; 2 mg/kg on days 1 ± 10), carboplatin (CPt; 60 mg/kg on day 1), or carboplatin given in combination with squalamine (SQ/CPt). At the end of the experiment, HER-2 receptor expression levels were assessed and, as possible, con®rmed to be low in parental tumors and high in HER-2-overexpressing xenografts. Results are given as mean+s.e.m. for tumor volumes (mm 3 ) measured over a 28-day experimental period. (b) CAOV3 ovarian cancer cells were inoculated subcutaneously in nude mice. After 7 days, animals with tumors of comparable size were randomized to treatment with control solution (CON), squalamine (SQ; 2 mg/kg on days 1 ± 10), cisplatin (Pt; 4 mg/kg on day 1), or cisplatin administered in combination with squalamine (SQ/Pt). Tumor volumes (mm 3 ) are expressed as mean+s.e.m. for measurements to assess tumor growth delay due to the several treatments (Teicher et al., 1998) xenografts remaining after treatments with squalamine, cisplatin (4 mg/kg dose; Pt 1) or a combination of the reagents were harvested at day 28 and assessed for ovarian tumor cell apoptosis in vivo. For evaluation of apoptosis, the modi®ed TUNEL assay (Ellis et al., 1991; Steller, 1995) was performed on tissue sections. The assays showed evidence of increased apoptosis in ovarian 2008 parental tumor cells treated with squalamine alone, cisplatin or combined cisplatinsqualamine as compared to appropriate controls (all at P50.05) (Figure 3a) . The 2008 HER-2-overexpressing ovarian tumors displayed less apoptotic activity than 2008 parental cancers with all treatments (P50.05). Although apoptosis tended to be higher after administration of either squalamine or cisplatin alone, only treatment with squalamine in combination with cisplatin elicited a signi®cant increase in the extent of apoptosis of HER-2-overexpressing ovarian cancers (P50.001) (Figure 3a) . The results suggest that squalamine enhances cytotoxic eects of cisplatin chemotherapy for human ovarian cancer cells by increasing levels of tumor cell apoptosis produced by cisplatin exposure, either with or without HER-2 oncogene overexpression. No signi®cant dierences in microvessel density were found between groups treated with cisplatin alone and controls. The results suggest that squalamine is antiangiogenic for ovarian cancer cells with or without HER-2 overexpression. Squalamine-induced suppression of tumor microvessels is also a sustainable event since it was noted up to 18 days following the last squalamine dose.
In further studies on expression of VEGF in tumor xenografts in vivo, ovarian 2008 parent and HER-2-overexpressing tumors were freshly excised at the end of the experiment (day 28) and dissected free of contaminating mouse tissue. The tumor xenografts were then dissociated and homogenized for further analysis of VEGF expression by Western blot (Figure 4) . Under nonreducing conditions, protein bands of the appropriate molecular size occur in both 2008 parent and HER-2-overexpressing tumors (Ferrara et al., 1993) . Moreover, 2008 HER-2-overexpressing tumors appear to have signi®cantly higher levels of VEGF than the 2008 parent tumors (Figure 4) . Among parental and HER-2-overexpressing tumors treated in vivo with squalamine, levels of VEGF were comparable to those of appropriate paired controls (Figure 4 ), suggesting that squalamine treatment does not in¯uence tumor-induced VEGF production.
Squalamine blocks VEGF-stimulated proliferation of endothelial cells in vitro
To assess the biologic mechanism for the antiangiogenic and antitumor eects of squalamine noted with the ovarian 2008 parent and 2008 HER-2-overexpressing tumor xenografts, human Squalamine does not affect VEGF secretion in vitro for ovarian cancer cells with or without HER-2 gene overexpression HER-2 overexpression is generally thought to lead to tumor development through its eects on promoting uncontrolled cancer cell growth. However, recent ®ndings suggest that HER-2 may also regulate cell survival functions such as angiogenesis by promoting tumor production of VEGF (Petit et al., 1997) . To explore how HER-2 may contribute to angiogenesis in ovarian cancers, we evaluated HER-2 eects on in vitro VEGF secretion by human ovarian tumor cells. Parent and HER-2-overexpressing ovarian 2008 cancer cells were incubated for 72 h in vitro, and secretion of VEGF into conditioned media was determined by use of established enzyme-linked immunosorbant assay (ELISA) (Ferrara et al., 1993; Petit et al., 1997) (Figure 6 ). Parent ovarian cancer cells show signi®cant secretion of VEGF, and, after transfection of ovarian cells with HER-2 gene to high levels, a further increase in the level of VEGF secretion was found, a result consistent with the in vivo ®ndings described above (see Figure 4 ). In parallel in vitro studies, treatment of ovarian cancer cells with squalamine elicited no signi®cant eect on secretion of VEGF (Figure 6 ), again reminiscent of our in vivo ®ndings. Thus, HER-2 overexpression may contribute to angiogenesis through up-regulation of VEGF secretion in ovarian cancer, but squalamine is not anti-angiogenic at this step in tumor-associated angiogenesis since it does not appear to directly aect secretion of VEGF by ovarian epithelial tumor cells. Alitalo, 1995; Soker et al., 1996) . Post-receptor signal transduction regulates the eects of VEGF, and the proliferative action of VEGF in endothelial cells has been associated with VEGFinduced tyrosine phosphorylation and stimulation of mitogen-activated protein kinases (MAP kinase), extracellular signal-regulated kinase ERK-1 (p44 MAPK ) and ERK-2 (p42 MAPK ) (Soker et al., 1996; Rousseau et al., 1997) . On the assumption that blockade of endothelial cell proliferation by squalamine may occur, in part, by suppression of MAP kinase signaling cascades induced by growth factors, VEGF-induced tyrosine phosphorylation of MAP kinases was assessed. As expected, VEGF promotes tyrosine phosphorylation of MAP kinase isoforms, with maximal eects evident by 10 min (Figure 7 ). However, after administration of squalamine, the VEGF-stimulated phosphorylation of MAP kinase isoforms is signi®cantly suppressed, especially after 30 min exposure to VEGF (Figure 7 ).
Discussion
It is well-known that solid tumors are angiogenesisdependent for growth, and angiogenesis is stimulated by tumor-secreted angiogenic factors, such as VEGF, that bind to tyrosine kinase receptors and promote endothelial cell proliferation and new capillary formation (Folkman, 1971; Gimbrone et al., 1972; Folkman and Haudenschild, 1980) . Similarly, the present studies suggest that angiogenesis is essential for growth of ovarian tumors in vivo. Squalamine, a natural antiangiogenic steroid, blocks VEGF-induced growth of human umbilical vein endothelial cells, suggesting it presumptively could have a positive role in regulating the growth of ovarian cancers. The experiments described in this paper show further that squalamine suppresses in vivo growth of ovarian cancer xenografts to a similar extent with or without HER-2 oncogene overexpression in the tumor and enhances the cytotoxic eects of platinum-based chemotherapy. Resistance to cisplatin treatment in ovarian tumors with or without HER-2-overexpression may therefore be overcome when the cisplatin is combined with squalamine, a feature of squalamine that could have direct application to the design of appropriate clinical trials.
Several studies suggest that VEGF plays an important role in the progression of ovarian cancer (Paley et al., 1997; Yamamoto et al., 1997; Alvarez et al., 1999) , and evidence for interactions between VEGFinduced angiogenesis and growth factor receptor pathways in tumors is beginning to emerge. Since the HER-2 growth factor receptor is overexpressed in a signi®cant number of ovarian cancers, it may play an important role in promoting growth of ovarian cancers (Slamon et al., 1989; Wong et al., 1995; Juhl et al., 1997; Hellstrom et al., 2001 ). In the laboratory, HER-2 ampli®cation is rate-limiting for expression of the malignant phenotype of ovarian cancer in a dosedependent manner (Juhl et al., 1997) , and HER-2 antireceptor antibodies elicit cytostatic growth inhibition of ovarian cancer cells overexpressing HER-2 (Pietras et al., 1994) . We have demonstrated in this paper that VEGF is produced by transfected and nontransfected human ovarian 2008 cancers, and stimulation of the HER-2 pathway appears to further upregulate tumor secretion of VEGF. In our studies on VEGF expression in ovarian 2008 tumor xenografts in vivo, ovarian 2008 tumors overexpressing HER-2 were associated with signi®cantly higher levels of VEGF than ovarian 2008 parent control tumors, consistent with data from the in vitro experiments with the same cancer cells. These ®ndings correspond well with prior observations on the stimulatory in¯uence of HER-2 signaling on VEGF production in human breast cancers (Petit et al., 1997) . The data also are consistent with clinical data demonstrating HER-2 oncogene overexpression is associated with a poor prognosis for ovarian cancer patients with this abnormality (Slamon et al., 1989; Berchuck et al., 1990; Wong et al., 1995) . In these individuals, VEGF overproduction may stimulate angiogenesis to a greater extent than would otherwise be seen, leading to rapid tumor growth and shorter patient survival times.
Squalamine speci®cally inhibits endothelial cell proliferation induced by a wide range of growth factors, including VEGF. This inhibition may result from its interaction with endothelial cell surface proton pumps, thus altering intracellular pH and impeding downstream signaling by growth factors (Akhter et al., 1999; Eckhardt, 1999) . Alternatively, calcium-dependent cell signaling following exposure to growth factors such as VEGF may be dysregulated when squalamine forces intracellular redistribution of calmodulin (Chen et al., 1999) . Irrespective of which mechanism may be operating, we ®nd that squalamine blocks proliferation of human umbilical vein endothelial cells in vitro, while it does not directly interfere with growth of ovarian tumor cells or production of VEGF by these tumor cells in vitro. VEGF has been shown to initiate biologic responses by binding with receptor tyrosine kinases, including Flt-1, Flk-1/KDR and neuropilin, present at the surface of endothelial cells (Mustonen and Alitalo, 1995; Soker et al., 1998; Abedi and Zachary, 1997) . The proliferative action of VEGF in endothelial cells is associated with the subsequent VEGF-induced tyrosine phosphorylation and stimulation in concert of focal adhesion kinase (FAK) and MAP kinases, including p38 MAP kinase, ERK-1 (p44 MAPK ) and ERK-2 (p42 MAPK ) (Soker et al., 1996; Rousseau et al., 1997; Kroll and Waltenberger, 1997) . On testing the assumption that blockade of endothelial cell proliferation by squalamine may occur, in part, by suppression of MAP kinase signaling cascades induced by VEGF in endothelial cells, we found that squalamine signi®-cantly curbs VEGF-stimulated phosphorylation of MAP kinase isoforms p42 and p44 in HUVEC. Thus, squalamine may prevent endothelial cell growth and associated angiogenesis by interrupting signal transduction necessary for endothelial cell activation. In addition, administration of squalamine alone to nude mice with human ovarian cancer xenografts elicits a partial reduction in tumor size as compared to controls in both parental and HER-2-overexpressing tumors. This in vivo eect of squalamine is further enhanced by coadministration of cisplatin and is associated with a reduction of tumor-associated angiogenesis and with enhanced apoptosis of ovarian cancer cells with both 2008 tumor lines, notably when squalamine and cisplatin are used together. The chemotherapeutic eect on apoptosis presumably is due to interruption of the tumor-associated blood supply. Given the relatively small response of both ovarian tumor lines to cisplatin treatment, it is noteworthy that cisplatin plus squalamine is a far better treatment than squalamine alone, and the combination has similar antitumor ecacy with both tumor lines. As in the experiments described above with ovarian cancers, squalamine alone was previously reported to be a potent inhibitor of the growth of blood vessel cells in preclinical studies of lung (Teicher et al., 1998; Schiller and Bittner, 1999 ) and brain (Sills et al., 1998) cancers. To evaluate the possible clinical ecacy of squalamine combined with standard cytotoxic antitumor therapy in suppressing growth of ovarian cancers, the anti-angiogenic sterol was administered to the 2008 parent and 2008 HER-2-overexpressing tumor xenografts in combination with cisplatin and to CAOV3 HER-2-overexpressing tumors in combination with cisplatin or carboplatin chemotherapy. Use of postoperative chemotherapy is standard treatment for all advanced-stage and for many early-stage patients with ovarian cancer, and adjuvant therapy with platinum-based regimens signi®cantly prolongs survival (Ozols, 1999) . The experimental results provide evidence of signi®cant antitumor ecacy of the several ovarian cancers following combined treatment with squalamine and cisplatin (or carboplatin) as compared with appropriate controls. These results are consistent with earlier studies demonstrating enhancement by squalamine of the antitumor ecacy of cisplatin, carboplatin or carboplatin/paclitaxel therapies in nude mice with lung cancer xenografts (Teicher et al., 1998; Schiller and Bittner, 1999) . Data in this paper show a strong correlation between the ability of squalaminebased chemotherapy to inhibit tumor angiogenesis and tumor growth and increase tumor apoptosis. Since platinum-based chemotherapies are often used for treatment of ovarian cancers (Ozols, 1999) , extrapolation of our experimental results to the clinical setting leads us to infer squalamine in combination with platinum compounds may prove useful as part of a coordinated attack against both ovarian tumor blood supply and ovarian cancers.
Squalamine has been tested in two phase I clinical trials employing patients with a variety of solid malignancies and who have failed conventional therapies, and the chemical has been shown to be well-tolerated by human subjects (Patnaik et al., 1999) . Phase II combination chemotherapy studies incorporating squalamine are ongoing in patients with advanced ovarian cancer. The outcome of these clinical trials will provide the ®rst answers as to whether or not squalamine oers a degree of outcome improvement over cytotoxic therapy alone to patients aicted with disseminated ovarian cancer comparable to that seen with the xenograft models described in this report.
Materials and methods

Cell lines
Human ovarian 2008 parental cells (provided by Dr S Howell) were derived from a patient with serous cystadenocarcinoma of the ovary (Disaia et al., 1972) , and human CAOV3 ovarian carcinoma cells were obtained from American Type Culture Collection (Rockville, MD, USA). Using methods described elsewhere (Chazin et al., 1992; Pietras et al., 1994; Pegram et al., 1997) , ovarian cancer cells with low expression of HER-2 gene were stably transfected with a vector containing the full-length cDNA of human HER-2 gene, with molecular characterization of HER-2 overexpression as before (Pietras et al., 1994; Pegram et al., 1997) . Both parental and HER-2-overexpressing ovarian cancer cells were routinely cultured in RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum, 2 mM freshly added glutamine and 1% penicillin G-streptomycin-fungizone solution (Irvine Scienti®c, Santa Ana, CA, USA). Human umbilical vein endothelial cells were obtained from Clonetics (San Diego, CA, USA), with immunospeci®c staining to con®rm that cells are endothelial (Morales et al., 1995) . The latter cells were grown in endothelial cell growth medium (EGM) which contains endothelial cell basal medium supplemented with 2% fetal bovine serum, 10 ng/ml hEGF, 1.0 mg/ml hydrocortisone, 50 mg/ml gentamicin, 50 ng/ml amphotericin-B, and 12 mg/ml bovine brain extract (BBE) (Folkman and Haudenschild, 1980; Morales et al., 1995) .
Measurement of VEGF protein levels
Secretion of VEGF protein was quantitated in extracellular media by enzyme-linked immunosorbant assay (ELISA) after centrifugation and concentration by Amicon 1 ®ltration (Ferrara et al., 1993; Goldman et al., 1993) .
Quantitation of cell proliferation in vitro
Human ovarian tumor or endothelial cells (10 000 cells/well) were plated in 12-well plates and allowed to attach overnight in the appropriate complete media. The medium was then removed and replaced with either fresh complete medium, medium supplemented with squalamine, VEGF (PeproTech, Rocky Hill, NJ, USA), or squalamine plus VEGF. The choice of squalamine doses for use in the in vitro studies was based on results from preliminary experiments and pharmacokinetic studies (Williams et al., 2001) . Cell proliferation was determined by both direct counts and Coulter-counter analyses. All assays were performed in triplicate.
Detection of p44/42 MAP kinase activity by Western blot
Tyrosine phosphorylation of MAP kinase was determined as before (Sebolt-Leopold et al., 1999) . HUVEC cells were grown in 100 mm culture dishes to 80 ± 90% con¯uence and in complete EGM media. Then, cells were starved in endothelial cell basal medium containing 1% fatty acid-free, steroid-depleted bovine serum albumin for 8 h. Prior to addition of VEGF (50 ng/ml) for various times at 378C, cells were incubated in the presence or absence of 1.6 mM squalamine for 1 h. After treatment, cells were immediately rinsed with cold PBS three times and chilled at 0 ± 48C prior to lysis in 100 ml cold lysis buer containing 20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol, 1% Triton X-100, 20 mM EDTA, 0.5 mg/ml leupeptin, 0.5 mg/ml aprotinin, 50 mg/ml trypsin inhibitor, 0.1 mg/ml 4-(2-aminoethyl)-benzenesulfonyl¯uoride and 1.0 mM sodium orthovanadate (Sigma, St. Louis, MO, USA). Total protein concentration was determined by BCA assay (Pierce Biochemical, Rockford, IL, USA). Protein samples (50 mg/lane) were separated on a 4 ± 12% precast Tris-Glycine gel (Novex, San Diego, CA, USA). Proteins were then transferred to a nitrocellulose membrane and subjected to immunodetection with antiphospho-p44/p42 MAP kinase E10 monoclonal antibody (New England Biolabs, Beverly, MA, USA), using the ECL Western blotting system (Amersham Pharmacia, Arlington Heights, IL, USA) as before (Chazin et al., 1992; Pegram et al., 1997) . In paired control experiments, a p44/p42 MAP kinase antibody (New England Biolabs) was used for detection of total enzyme protein.
Tumor cell inoculation and drug treatment in nude mice
All animal studies were conducted according to protocols approved by the UCLA animal research committee. Five to six-week-old female athymic nude mice (25 ± 30 gm) were obtained from Harlan Sprague-Dawley (Indianapolis, IN, USA) and primed for 7 days with 17b-estradiol applied subcutaneously in a biodegradable carrier-binder (1.7 mg of estradiol per pellet, 60-day release form, Innovative Research of America, Sarasota, FL, USA). Thereafter, 2610 7 tumor cells were injected subcutaneously in the mid-back region of the mice and grown as xenografts (Pietras et al., 1994; Pegram et al., 1997) . After growth of tumors to 150 ± 200 mm 3 , animals were randomized by body weight and tumor nodule size to dierent treatment groups of 5 ± 7 mice. Animals were treated by intraperitoneal injection with control solution, cisplatin (Platinol), carboplatin (Paraplatin; Bristol Myers Squibb, Princeton, NJ, USA), squalamine (2 mg/kg on days 1 ± 10; Genaera Corporation, Plymouth Meeting, PA, USA) or cisplatin (or carboplatin) in combination with squalamine. Based on previous work (Pietras et al., 1994; Pegram et al., 1997; Schiller and Bittner, 1999; Plumb et al., 2000) , cisplatin (4 mg/kg) and carboplatin (60 mg/kg) were generally administered at doses less than the maximum tolerated dose in an attempt to allow any additive eects of combination treatment with platinum-based agents and squalamine to be more easily detected (Schiller and Bittner, 1999) . However, in selected experiments, cisplatin (5 mg/kg on day 1, 8) was also administered alone and in combination with squalamine at maximum tolerated doses as determined previously for these cell lines in nude mouse models (Pietras et al., 1994; Pegram et al., 1997; Kolfschoten et al., 2000) . The 2 mg/kg squalamine dose was selected as being the minimal daily dose previously shown to be signi®cantly active in a tumor xenograft model in combination with a platinum agent (Williams et al., 2001) . Tumor nodules were monitored by dimension measurements as before (Pietras et al., 1994) . In most studies, experiments were terminated after 28 days to allow harvesting of tumor xenografts for assessment of selected molecular endpoints, including HER-2 expression by immunohistochemical methods (see Pietras et al., 1994; Pegram et al., 1997) . Mean tumor growth inhibition for each treatment group was determined as before (Pietras et al., 1994; Pegram et al., 1997) . In selected experiments, tumor growth delay was calculated by graphing the volume of each treatment group and calculating the number of additional days it took to reach 500 mm 3 compared with control (Teicher et al., 1998) . In all studies, toxicities of treatment regimens were estimated by following changes in animal body weight and the incidence of drug-associated deaths.
Tissue preparation and paraffin-embedded tissue sections
At the end of the experiments, mice were sacri®ced, and tumors were excised, ®xed in formalin and embedded in paran according to established procedures (Luna, 1968) . Paran-embedded tumors were prepared in 4 ± 6 mm sections, mounted on positively-charged Superfrost Plus slides (Fisher, Houston, TX, USA) prior to immunohistochemical staining, and sections were then deparanized in xylene, followed by 100, 95, 70 and 50% ethanol and rehydration in H 2 O.
Quantification of tumor vessel counts
Histological sections of tumors from in vivo treatments of ovarian cancers were analysed for degree of angiogenesis by estimates of tumor-associated blood microvessel density. Tumor microvessel density was measured by counting the number of capillary blood vessels per high power ®eld in sections stained with antibodies against von Willebrand Factor (vWF) as before (O'Reilly et al., 1997) . In brief, anti-human vWF/HRP antibodies (EPOS; Dako, Carpinteria, CA, USA) were applied on tissue sections to mark endothelial cells and were then detected using a speci®c substrate system. Vessels were counted by use of a light microscope.
Apoptosis assay
Histological sections of tumors from in vivo treatments of ovarian cancers were analysed for apoptosis using a detection system described previously (Ellis et al., 1991; O'Reilly et al., 1997) . Apoptosis was assessed by a speci®c colorimetric detection system (Promega, Madison, WI, USA) (Ellis et al., 1991; Steller, 1995) . In brief, fragmented DNA of apoptotic cells were end-labeled using a modi®ed TUNEL (TdTmediated dUTP nick-end labeling) assay. Biotinylated nucleotide was incorporated at 3'-OH DNA ends using terminal deoxynucleotidyl transferase. Horseradish peroxidase-labeled streptavidin was then bound to biotinylated nucleotides and was detected using peroxidase substrate, hydrogen peroxide, and the stable chromogen diaminobenzidine. Using this procedure, apoptotic nuclei stained brown. An apoptotic index was estimated by the percentage of cells scored with a light microscope at 200-fold magni®cation (O'Reilly et al., 1997) .
Detection of VEGF in tumors
In selected in vivo experiments, human tumor xenografts were freshly excised and dissected free of mouse tissues. Human tumor tissue was then dissociated and homogenized in vitro by established methods (Pietras and Roberts, 1981) . Total protein concentration in homogenates was assessed by BCA assay (Pierce Biochemical), and protein samples were separated on a 4 ± 12% precast Tris-Glycine gel (Novex). Proteins were then transferred to a nitrocellulose membrane and subjected to immunodetection with anti-VEGF monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), using the ECL Western blotting system (Amersham Pharmacia) as before (Chazin et al., 1992; Pietras et al., 1994) .
Statistical analysis
Statistical evaluation of data by t-tests and analysis of variance as appropriate was conducted using methods described before (Pietras et al., 1994; Pegram et al., 1997) . All computations were made with Stat View and Super ANOVA software (Abacus Concepts, Berkeley, CA, USA).
